Eiger BioPharmaceuticals to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a biopharmaceutical company dedicated to rare diseases, will present a corporate update at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14, 2021, at 1:00 PM EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a biopharmaceutical company dedicated to rare diseases, will present a corporate update at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14, 2021, at 1:00 PM EDT. David Cory, President and CEO, will lead the presentation. A live webcast will be available on Eiger's website, with a replay accessible one hour post-event. Eiger is focused on therapies for Hepatitis Delta Virus and has FDA approval for Zokinvy®, targeting Hutchinson-Gilford Progeria Syndrome.
Details
News Market Reaction – EIGR
The recorded move for EIGR in the trading session of this news was -5.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., July 7, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and Chief Executive Officer of Eiger, will present a corporate update at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Wednesday, July 14, 2021 at 1:00 PM EDT.
A live webcast of the presentation will be available on the Eiger BioPharmaceuticals website at www.eigerbio.com under the "Investors" tab. A replay of the webcast will be available approximately one hour following the completion of the live event.
Eiger will also host virtual one-on-one meetings with investors.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
Eiger's lead clinical programs are focused on the development of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of viral hepatitis, with two complementary HDV treatments. Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon lambda is a first-in-class, type III, well-tolerated interferon entering Phase 3.
Zokinvy® for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies is the Company's first FDA approved product. A Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA).
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Investors and Media:
Charles Butler
Vice President, Investor Relations and Corporate Communications
Email: cbutler@eigerbio.com
Phone: 1-650-272-6138
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-ladenburg-thalmann-2021-virtual-healthcare-conference-301326717.html
SOURCE Eiger BioPharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.